What's new in psoriasis? An analysis of guidelines and systematic reviews published in 2009-2010

Clinical and Experimental Dermatology

Volumn 36, Issue 6, 2011, Pages 585-589

  Foulkes, A C ^a   Grindlay, D J C ^b   Griffiths, C E M ^a   Warren, R B ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; ETANERCEPT; ETRETIN; INFLIXIMAB; PSORALEN; TUMOR NECROSIS FACTOR ALPHA; USTEKINUMAB;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; DARIER DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; ERYTHRODERMIC PSORIASIS; HAND ECZEMA; HEALTH ECONOMICS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ICHTHYOSIS; KERATODERMA; MEDICAL SOCIETY; METABOLIC SYNDROME X; MONOTHERAPY; MULTIPLE SCLEROSIS; OBESITY; OUTCOME ASSESSMENT; PHOTOTHERAPY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PUSTULOSIS PALMOPLANTARIS; REVIEW; SKIN DISEASE; SYSTEMATIC REVIEW;

EID: 79960593968     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2011.04108.x     Document Type: Review

References (24)

1. Brown BC, Warren RB, Grindlay DJ, Griffiths CEM,. What's new in psoriasis? Analysis of the clinical significance of systematic reviews on psoriasis published in 2007 and 2008. Clin Exp Dermatol 2009; 34: 664-7.
2. Warren RB, Brown BC, Grindlay DJ, Griffiths CEM,. What's new in psoriasis? Analysis of the clinical significance of new guidelines and systematic reviews on psoriasis published in 2008 and 2009. Clin Exp Dermatol 2010; 35: 688-91.
3. Smith CH, Anstey AV, Barker JNWN, et al. British Association of Dermatologist's guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987-1019.
4. National Institute for Health and Clinical Excellence. Infliximab for the Treatment of Adults with Psoriasis. London: NICE, 2008.
5. Ormerod AD, Campalani E, Goodfield MJD,. British Association of Dermatologists guidlines on the efficacy and use of acitretin in dermatology. Br J Dermatol 2010; 162: 952-63.
6. Clinical Knowledge Summaries (CKS), Psoriasis. 2010. Available at: (accessed 17 May 2011)
7. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2009; 62: 114-35.
8. Taylor DK, Anstey AV, Coleman AJ, et al. British Photodermatology Group. Guidelines for dosimetry and calibration in ultraviolet radiation therapy: a report of a British Photodermatology Group workshop Guidelines for dosimetry and calibration in ultraviolet radiation therapy: a report of a British Photodermatology Group workshop. Br J Dermatol 2002; 146: 755-63.
9. Puzenat E, Bronsard V, Prey S, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol 2010; 24 (Suppl. 2): 10-16.
10. Bronsard V, Paul C, Prey S, et al. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol 2010; 24 (Suppl. 2): 17-22.
11. Tobin AM, Veale DJ, Fitzgerald O, et al. Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. J Rheumatol 2010; 37: 1386-94.
12. Pre S, Paul C, Bronsard V, et al. Cardiovascular risk factors in patients with plaque psoriasis. A systematic review of epidemiological studies. J Eur Acad Dermatol Venereol 2010; 24 (Suppl. 2): 23-30.
13. Bremmer S, van Voorhees AS, Hsu S, et al. Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2010; 63: 1058-69.
14. Kwok T, Jing Loo W, Guenther L,. Psoriasis and multiple sclerosis: is there a link? J Cutan Med Surg 2010; 14: 151-5.
15. Christophers E, Barker JNWN, Griffiths CEM, et al. The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Europ Acad Dermatol Venereol 2010; 24: 548-54.
16. Prey S, Paul C, Bronsard V, et al. Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. J Eur Acad Dermatol Venereol 2010; 24 (Suppl. 2): 31-5.
17. Rosenbach M, Hsu S, Korman NJ, et al. National Psoriasis Foundation Medical Board. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol 2010; 62: 655-62.
18. Frankel AJ, van Voorhees AS, Hsu S, et al. National Psoriasis Foundation. Treatment of psoriasis in patients with hepatitis C. from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2009; 61: 1044-55.
19. Menon K, van Voorhees AS, Bebo BF Jr, et al. National Psoriasis Foundation. J Am Acad Dermatol 2010; 62: 291-9.
20. Poulin Y, Langley RG, Teixeira HD, et al. Biologics in the treatment of psoriasis: clinical and economic overview. J Cutan Med Surg 2009; 13 (Suppl. 2): S49-57.
21. Gospodarevskaya E, Picot J, Cooper K, et al. Ustekinumab for the treatment of moderate to severe psoriasis. Health Technol Assess 2009; 13 (Suppl 3): 61-66.
22. Turner D, Picot J, Cooper K, et al. Adalimumab for the treatment of psoriasis. Health Technol Assess 2009; 13 (Suppl 2): 49-54.
23. National Institute for Health and Clinical Excellence (NICE). Ustekinumab for the Treatment of Adults with Moderate to Severe Psoriasis. London: NICE, 2009.
24. National Institute for Health and Clinical Excellence (NICE). Adalimumab for the Treatment of Adults with Psoriasis. London: NICE, 2008.